Vaxxinity, Inc. (VAXX) Income Statement
VAXX 2023 at a glance
Fiscal year ended December 31, 2023 · U.S. dollarsVAXX revenue and net income
VAXX profit margins
VAXX growth rates
to 2023| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VAXX quarterly EPS vs estimates
Vaxxinity beat the analyst EPS estimate in 8 of the last 8 quarters.
VAXX income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $66,000 | $557,000 | $0 |
| Cost of revenue | $2.2M | $1.7M | $1.9M | $52,000 | $107,000 |
| Gross profit | −$2.2M | −$1.7M | −$1.9M | $505,000 | −$107,000 |
| Research & development | $33.7M | $47.6M | $71.4M | $20.6M | $10.7M |
| Sales, general & admin | $22.4M | $28.4M | $51.8M | $12.2M | $3.0M |
| Total operating expenses | $56.1M | $74.3M | $123.2M | $32.8M | $13.7M |
| Operating income | −$58.3M | −$76.0M | −$125.1M | −$32.3M | −$13.7M |
| Interest income | $2.3M | $1.3M | $9,000 | $1,000 | — |
| Interest expense | $696,000 | $514,000 | $840,000 | $1.2M | $435,000 |
| Income before taxes | −$56,934 | −$75.2M | −$137.2M | −$40.0M | −$14.2M |
| Income taxes | −$56,934 | −$12,000 | $840,000 | −$4.6M | $56,000 |
| Net income | −$56,934 | −$75.2M | −$137.2M | −$40.0M | −$14.2M |
| EBITDA | −$54.0M | −$73.0M | −$135.2M | −$38.1M | −$13.6M |
| EPS (diluted) | −$0.45 | −$0.60 | −$1.26 | −$0.83 | −$0.11 |
| Gross margin | — | — | −2,834.8% | 90.7% | — |
| Operating margin | — | — | −189,507.6% | −5,795.7% | — |
| Net margin | — | — | −207,840.9% | −7,173.6% | — |
| Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | Sep '21 | Jun '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $50,000 | $0 |
| Cost of revenue | $456,000 | $456,000 | $666,000 | $512,000 | $600,000 | $540,000 | $419,000 | $392,000 | $333,000 | $174,000 | $9,000 | $1.9M |
| Gross profit | −$456,000 | −$456,000 | −$666,000 | −$512,000 | −$600,000 | −$540,000 | −$419,000 | −$392,000 | −$333,000 | −$175,000 | $41,000 | −$1.9M |
| Research & development | $7.8M | $7.8M | $7.9M | $8.3M | $11.4M | $13.0M | $12.5M | $10.7M | $11.5M | $17.2M | $23.6M | $18.9M |
| Sales, general & admin | $3.4M | $3.4M | $5.5M | $6.1M | $7.4M | $7.8M | $7.3M | $6.6M | $6.7M | $30.7M | $6.7M | $5.9M |
| Total operating expenses | $11.2M | $11.2M | $13.4M | $14.4M | $18.8M | $20.8M | $19.8M | $17.2M | $18.2M | $47.9M | $30.3M | $24.9M |
| Operating income | −$11.7M | −$11.7M | −$13.4M | −$14.4M | −$18.8M | −$20.8M | −$19.8M | −$17.2M | −$18.2M | −$47.9M | −$30.3M | −$26.8M |
| Interest income | — | $433,000 | $512,000 | $578,000 | $567,000 | $634,000 | $545,000 | $75,000 | $5,000 | — | — | — |
| Interest expense | $182,000 | $182,000 | $176,000 | $146,000 | $192,000 | $250,000 | $54,000 | $105,000 | $105,000 | $338,000 | $112,000 | $109,000 |
| Income before taxes | −$11.4M | −$11.4M | −$13.1M | −$14.0M | −$18.4M | −$20.5M | −$19.3M | −$17.3M | −$18.3M | −$48.2M | −$30.4M | −$26.8M |
| Income taxes | $412,188 | $412,188 | $176,000 | $146,000 | −$12,000 | $16,000 | $54,000 | $28,000 | −$1,000 | $3.0M | $109,000 | $107,000 |
| Net income | −$11.4M | −$11.4M | −$13.1M | −$14.0M | −$18.4M | −$20.5M | −$19.3M | −$17.3M | −$18.3M | −$48.2M | −$30.4M | −$26.9M |
| EBITDA | −$11.2M | −$10.8M | −$12.3M | −$13.3M | −$17.6M | −$19.7M | −$18.8M | −$16.8M | −$17.8M | −$47.7M | −$29.9M | −$26.5M |
| EPS (diluted) | $0.00 | −$0.09 | −$0.10 | −$0.11 | −$0.15 | −$0.16 | −$0.15 | −$0.14 | −$0.15 | −$0.19 | −$0.24 | −$0.44 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | 82.0% | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — | −60,550.0% | — |
| Net margin | — | — | — | — | — | — | — | — | — | — | −60,778.0% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VAXX's financial statements (latest annual report filed March 27, 2024); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VAXX financial results
Vaxxinity reported no revenue in fiscal year 2023 (ended December 31, 2023). It had a net loss of $0.1 million. Diluted earnings per share came to −$0.45.
See the VAXX stock overview for the latest quote and news, or the VAXX chart for price history and technical indicators.
VAXX income statement FAQ
Does Vaxxinity have revenue?
Vaxxinity reported no revenue for fiscal year 2023, which ended on December 31, 2023.
Is Vaxxinity profitable?
No. Vaxxinity reported a net loss of $0.1 million in fiscal 2023.
How much does Vaxxinity spend on research and development?
Vaxxinity spent $33.7 million on research and development in fiscal 2023.
What are Vaxxinity's earnings per share?
Vaxxinity earned $-0.45 per diluted share in fiscal 2023, compared with $-0.60 a year earlier.
When does Vaxxinity's fiscal year end?
Vaxxinity's fiscal year ends in December. The latest annual report covers the year ended December 31, 2023 and was filed on March 27, 2024.